Leondios G. Kostrikis

Last updated
Leondios G. Kostrikis
Born (1963-04-20) April 20, 1963 (age 61)
Nicosia, Cyprus
NationalityCypriot
Known forRole of human genetics in HIV-1 transmission and AIDS disease progression
AwardsFulbright Scholar, Member of Cyprus Academy of Sciences, Letters, and Arts, Member of Academia Europaea
Scientific career
FieldsMolecular Virology
Institutions University of Cyprus

Leondios G. Kostrikis (born April 20, 1963) is a molecular virologist from Cyprus and a professor of molecular virology at the University of Cyprus. He is a founding member of the Cyprus Academy of Sciences, Letters and Arts and a member of Academia Europaea. In 2022, he attracted media attention with the news of having found a "Deltacron" Coronavirus variant, a recombinant between Delta and Omicron strains. The emergence of this phenomenon initially evoked scepticism, characterized by concerns primarily centered around contamination or coinfection as plausible etiological contributors. These hypotheses were predominantly disseminated through unsubstantiated assertions within the realms of social and mass media, lacking concurrent scientific evidence to validate their claims. Comparable observations on a global scale dispelled doubt, eventually leading to the recognition of Delta-Omicron variants by the scientific community and their subsequent monitoring by the World Health Organization.

Contents

Early life and education

Kostrikis was born in Cyprus. [1] He received his scientific education in Biochemistry from New York University. In 1987, he received his B.Sc. degree, supported by a Fulbright Scholarship. In 1993, he received his Ph.D. from the same university [1]

Career

He moved to Aaron Diamond AIDS Research Center (ADARC) to do HIV-1 research. In 1999, he was appointed Assistant Professor of Rockefeller University. [1] In 2003, he returned to Cyprus. He became Head of Laboratory of Biotechnology and Molecular Virology and Professor of Molecular Virology at the University of Cyprus. [1] In 2019, he was elected as a Founding Member (Biological Sciences) of The Cyprus Academy of Sciences, Letters and Arts and in 2020, he was elected as Member of the Biosciences Steering Panel of the European Academies Science Advisory Council (EASAC) and as a Distinguished Fellow of the International Engineering and Technology Institute (IETI). In 2020, he received the Cyprus Distinguished Researcher Award in Life Sciences from the Research and Innovation Foundation in Cyprus. In 2024, he was elected as a Member of The Academia Europaea (Academy of Europe) in the Section of Biochemistry and Molecular Biology

SARS-CoV-2 Deltacron hybrid variant

Following the emergence of COVID-19 Omicron variant, Kostrikis announced in January 2022 in local TV [2] that his Cypriot health research team in Nicosia had found a new COVID-19 variant dubbing it "Deltacron". [3] Following the initial announcement, indiscriminate news of the COVID-19 hybrid variant dubbed "Deltacron" spread quickly in mainstream media. [4] [5] [6] [7]

Maria Van Kerkhove (WHO's COVID-19 Technical Leader), Krutika Kuppalli (member of WHO's COVID-19 Technical Team) and Thomas Peacock, a postdoctoral fellow (Imperial College London) challenged this announcement, saying a lab mistake was a more probable explanation for Cyprus lab's finding, although they did not provide any experimental data refuting the finding. [8] Initially, some journalists have argued, without providing any experimental data, that it is most likely the result of a lab contamination, which purportedly shares specific properties with two different strains. [9] [10] Kostrikis' team has published a peer-reviewed study, providing experimental data that confirms the original observation about Deltacron was correct. [11] Additionally, substantial scientific evidence has been produced since then, supporting the existence of Deltacron (Delta-Omicron) viruses, characterized by Delta (AY.4, AY.x) and Omicron (BA.1, BA.1.1, BA.2, BA.x) variants, which have been identified and verified by various laboratories around the world https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008264/ https://journals.lww.com/annals-of-medicine-and-surgery/fulltext/2022/07000/deltacron_is_a_recombinant_variant_of_sars_cov_2.104.aspx The identification and phylogenetic analysis of SARS-CoV-2 delta variants in Taiwan Incipient Parallel Evolution of SARS-CoV-2 Deltacron Variant in South Brazil

Related Research Articles

Professor Ravindra "Ravi" Kumar Gupta is a professor of clinical microbiology at the Cambridge Institute of Therapeutic Immunology and Infectious Disease at the University of Cambridge. He is also a member of the faculty of the Africa Health Research Institute in Durban, South Africa.

<span class="mw-page-title-main">Wuhan Institute of Virology</span> Research Institute in Wuhan, Hubei, China

The Wuhan Institute of Virology, Chinese Academy of Sciences is a research institute on virology administered by the Chinese Academy of Sciences (CAS), which reports to the State Council of the People's Republic of China. The institute is one of nine independent organisations in the Wuhan Branch of the CAS. Located in Jiangxia District, Wuhan, Hubei, it was founded in 1956 and opened mainland China's first biosafety level 4 (BSL-4) laboratory in 2018. The institute has collaborated with the Galveston National Laboratory in the United States, the Centre International de Recherche en Infectiologie in France, and the National Microbiology Laboratory in Canada. The institute has been an active premier research center for the study of coronaviruses.

Susan R. Weiss is an American microbiologist who is a Professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania. She holds vice chair positions for the Department of Microbiology and for Faculty Development. Her research considers the biology of coronaviruses, including SARS, MERS and SARS-CoV-2. As of March 2020, Weiss serves as Co-Director of the University of Pennsylvania/Penn Medicine Center for Research on Coronavirus and Other Emerging Pathogens.

<span class="mw-page-title-main">SARS-CoV-2 in mink</span>

Both the American mink and the European mink have shown high susceptibility to SARS-CoV-2 since the earliest stages of the COVID-19 pandemic, first in mink farms across Europe, followed by mink farms in the United States. Mortality has been extremely high among mink, with 35–55% of infected adult animals dying from COVID-19 in a study of farmed mink in the U.S. state of Utah.

<span class="mw-page-title-main">Variants of SARS-CoV-2</span> Notable variants of SARS-CoV-2

Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are viruses that, while similar to the original, have genetic changes that are of enough significance to lead virologists to label them separately. SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Some have been stated, to be of particular importance due to their potential for increased transmissibility, increased virulence, or reduced effectiveness of vaccines against them. These variants contribute to the continuation of the COVID-19 pandemic.

<span class="mw-page-title-main">Origin of SARS-CoV-2</span> Inquiries into the origins of SARS-CoV-2

Since the beginning of the COVID-19 pandemic, there have been efforts by scientists, governments, and others to determine the origin of the SARS-CoV-2 virus. Similar to other outbreaks, the virus was derived from a bat-borne virus and most likely was transmitted to humans via another animal in nature, or during wildlife trade such as that in food markets. While other explanations, such as speculations that SARS-CoV-2 was accidentally released from a laboratory have been proposed, such explanations are not supported by evidence. Conspiracy theories about the virus's origin have also proliferated.

Gain-of-function research is medical research that genetically alters an organism in a way that may enhance the biological functions of gene products. This may include an altered pathogenesis, transmissibility, or host range, i.e., the types of hosts that a microorganism can infect. This research is intended to reveal targets to better predict emerging infectious diseases and to develop vaccines and therapeutics. For example, influenza B can infect only humans and harbor seals. Introducing a mutation that would allow influenza B to infect rabbits in a controlled laboratory situation would be considered a gain-of-function experiment, as the virus did not previously have that function. That type of experiment could then help reveal which parts of the virus's genome correspond to the species that it can infect, enabling the creation of antiviral medicines which block this function.

<span class="mw-page-title-main">COVID-19 lab leak theory</span> Proposed theory on the origins of COVID-19

The COVID-19 lab leak theory, or lab leak hypothesis, is the idea that SARS-CoV-2, the virus that caused the COVID-19 pandemic, came from a laboratory. This claim is highly controversial; most scientists believe the virus spilled into human populations through natural zoonosis, similar to the SARS-CoV-1 and MERS-CoV outbreaks, and consistent with other pandemics in human history. Available evidence suggests that the SARS-CoV-2 virus was originally harbored by bats, and spread to humans from infected wild animals, functioning as an intermediate host, at the Huanan Seafood Market in Wuhan, Hubei, China, in December 2019. Several candidate animal species have been identified as potential intermediate hosts. There is no evidence SARS-CoV-2 existed in any laboratory prior to the pandemic, or that any suspicious biosecurity incidents happened in any laboratory.

<span class="mw-page-title-main">SARS-CoV-2 variant of concern</span> Highly transmissible and virulent strains of SARS-CoV-2

The term variant of concern (VOC) for SARS-CoV-2, which causes COVID-19, is a category used for variants of the virus where mutations in their spike protein receptor binding domain (RBD) substantially increase binding affinity in RBD-hACE2 complex, while also being linked to rapid spread in human populations.

Jemma Louise Geoghegan is a Scottish-born evolutionary virologist, based at the University of Otago, New Zealand, who specialises in researching emerging infectious diseases and the use of metagenomics to trace the evolution of viruses. As a leader in several government-funded research projects, Geoghegan became the public face of genomic sequencing during New Zealand's response to COVID-19. Her research has contributed to the discussion about the likely cause of COVID-19 and the challenges around predicting pandemics. She was a recipient of the Young Tall Poppy Award in 2017, a Rutherford Discovery Fellowship in 2020, and the 2021 Prime Minister's Emerging Scientist Prize.

<span class="mw-page-title-main">SARS-CoV-2 Delta variant</span> Variant of SARS-CoV-2 detected late 2020

The Delta variant (B.1.617.2) was a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India on 5 October 2020. The Delta variant was named on 31 May 2021 and had spread to over 179 countries by 22 November 2021. The World Health Organization (WHO) indicated in June 2021 that the Delta variant was becoming the dominant strain globally.

<span class="mw-page-title-main">V-01</span> Vaccine candidate against COVID-19

V-01 is a protein subunit COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc.

<span class="mw-page-title-main">Alex Sigal</span> Virologist, biologist

Alex Sigal is a South Africa–based virologist at the Africa Health Research Institute (AHRI) in Durban, South Africa, Max Planck Institute for Infection Biology in Berlin, and University of KwaZulu-Natal in Durban. His work concentrates on evolution and persistence of the SARS-CoV-2 virus. His laboratory was the first to isolate the live B.1.351 (Beta) variant of SARS-CoV-2 first detected in South Africa. Sigal’s laboratory was also the first to report results on the ability of the Omicron variant to escape antibody neutralization in individuals who had two doses of the Pfizer BNT162b2 vaccine as well as from previous infections, with results also suggesting that vaccination combined with a booster or previous infection can offer protection from symptomatic infection with Omicron.

<span class="mw-page-title-main">Noora (vaccine)</span> Vaccine candidate against COVID-19

Noora is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. in Iran. Introduced in June 2021, it was announced as having "successfully passed the first phase of its clinical trial" two months later.

<span class="mw-page-title-main">SARS-CoV-2 Omicron variant</span> Type of the virus first detected in November 2021

Omicron (B.1.1.529) is a variant of SARS-CoV-2 first reported to the World Health Organization (WHO) by the Network for Genomics Surveillance in South Africa on 24 November 2021. It was first detected in Botswana and has spread to become the predominant variant in circulation around the world. Following the original B.1.1.529 variant, several subvariants of Omicron have emerged including: BA.1, BA.2, BA.3, BA.4, and BA.5. Since October 2022, two subvariants of BA.5 called BQ.1 and BQ.1.1 have emerged.

William Paul Duprex is a British scientist and advocate for vaccines and global health. He serves as Director of the University of Pittsburgh's Center for Vaccine Research and Regional Biocontainment Laboratory. Duprex holds the Jonas Salk Chair in Vaccine Research. He is also a professor of microbiology and molecular genetics at the University of Pittsburgh School of Medicine and serves as Editor-in-Chief of the Journal of General Virology, which is published by the Microbiology Society, and a senior editor of mSphere, published by the American Society for Microbiology. Duprex is an expert in measles and mumps viruses and studies viral spillover from animals to humans, including the SARS-CoV-2 virus that caused the COVID-19 pandemic. Duprex is a Fellow of the American Academy of Microbiology.

<span class="mw-page-title-main">SARS-CoV-2 in white-tailed deer</span>

Blood samples gathered by USDA researchers in 2021 showed that 40% of sampled white-tailed deer demonstrated evidence of SARS-CoV-2 antibodies, with the highest percentages in Michigan, at 67%, and Pennsylvania, at 44%. A later study by Penn State University and wildlife officials in Iowa showed that up to 80% of Iowa deer sampled from April 2020 through January 2021 had tested positive for active SARS-CoV-2 infection, rather than solely antibodies from prior infection. This data, confirmed by the National Veterinary Services Laboratory, alerted scientists to the possibility that white-tailed deer had become a natural reservoir for the coronavirus, serving as a potential "variant factory" for eventual retransmission back into humans.

Alexander L. Greninger is assistant director of the UW Medicine Clinical Virology Laboratory and a UW associate professor of Laboratory Medicine. His research is focused on genomic and proteomic characterization of a variety of human viruses and bacteria, with a focus on respiratory viruses and human herpesviruses.

<span class="mw-page-title-main">Sunit Kumar Singh</span> Indian molecular biologist

Sunit Kumar Singh is an Indian molecular virologist and professor of Molecular Immunology & Virology at the Institute of Medical Sciences, Banaras Hindu University. Currently he is the director of the Dr B R Ambedkar Center for Biomedical Research (ACBR), New Delhi.

Events in the year 2022 in Cyprus.

References

  1. 1 2 3 4 "Leondios G. Kostrikis, Ph.D." Retrieved 2022-01-11.
  2. ↑ Dr. Christian Kretschmer (Arzt) (31 January 2022). "Supervariante Deltakron gibt es nicht – Fehler durch Kontamination". Gelbe Liste (in German).
  3. ↑ Georgiou, Georgios (January 8, 2022). "Cyprus Finds Covid-19 Infections That Combine Delta and Omicron". Bloomberg News . Retrieved March 14, 2022.
  4. ↑ Lee, Bruce Y. (March 12, 2022). "New 'Deltacron' Covid-19 Coronavirus Variant Is A Recombinant Of Delta And Omicron". Forbes . Retrieved March 14, 2022.
  5. ↑ Snider, Mike (March 10, 2022). "There may be a new COVID variant, Deltacron. Here's what we know about it". USA Today . Retrieved March 14, 2022.
  6. ↑ Khan, Amir (January 17, 2022). "'Deltacron': Should we worry about new COVID-19 variants merging?". Al Jazeera . Retrieved March 14, 2022.
  7. ↑ Zimmer, Carl (March 11, 2022). "New 'Deltacron' Variant Is Rare and Similar to Omicron, Experts Say". The New York Times . Retrieved March 14, 2022.
  8. ↑ Kreier, Freda (January 21, 2022). "Deltacron: the story of the variant that wasn't". Nature . 602 (7895): 19. Bibcode:2022Natur.602...19K. doi:10.1038/d41586-022-00149-9. PMID   35058630 . Retrieved March 14, 2022.
  9. ↑ Lapid, Nancy (March 9, 2022). "Variant that combines Delta and Omicron identified; dogs sniff out virus with high accuracy". Reuters . Retrieved March 14, 2022.
  10. ↑ Gubernator, Sebastian (2022-01-10). "Experten halten angeblichen "Demikron"-Nachweis für Laborfehler" (in German). Die Welt, cited via MSN. Retrieved 2022-01-11. Translation: Experts say the "Demikron" finding is a lab mistake
  11. ↑ Chrysostomou, Andreas C.; Vrancken, Bram; Haralambous, Christos; Alexandrou, Maria; Gregoriou, Ioanna; Ioannides, Marios; Ioannou, Costakis; Kalakouta, Olga; Karagiannis, Christos; Marcou, Markella; Masia, Christina; Mendris, Michail; Papastergiou, Panagiotis; Patsalis, Philippos C.; Pieridou, Despo (2023-09-15). "Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022)". Viruses. 15 (9): 1933. doi: 10.3390/v15091933 . ISSN   1999-4915. PMC   10535466 . PMID   37766339.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.